Sai Parenterals posted a manifold increase in net profit to ₹13.25 crore in the fourth quarter ended March 31, 2026 compared with ₹1.59 crore in the corresponding quarter of previous financial year.

Total revenue of the Hyderabad-based company more than doubled at ₹198 crore in the quarter under review from ₹74 crore in the year-ago period. 

“The quarter marks the full consolidation of all its subsidiaries following its acquisition in November 2025 More importantly, our profitability has improved dramatically, EBITDA grew 366.79 per cent in Q4 and PAT surged 736 per cent which is clear evidence of the operating leverage in our model,’’ Anil KK, Managing Director, Sai Parenterals, said in a release. 

For the full year FY26, net profit increased 45 per cent to ₹14 crore (₹10 crore). The revenue more than doubled at ₹381 crore (₹158 crore). 

Sai Parenterals went for an IPO in March this year. Its portfolio includes formulation products across various therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology, with offerings across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. 

In the injectables segment, the company has capabilities in sterile manufacturing for critical care and antibiotics, delivered through dry powder injections, prefilled syringes, ampoules, and vials.

Published on May 25, 2026